LXRX Q3 2023 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$162,000+315.4% YoY

Gross Profit

$155,00095.7% margin

Operating Income

-$50M-30636.4% margin

Net Income

-$51M-31188.3% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-48.9%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$276M

Total Liabilities

$137M

Stockholders' Equity

$140M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$162,000	$39,000	+315.4%
Gross Profit	$155,000	$39,000	+297.4%
Operating Income	-$50M	-$23M	-114.9%
Net Income	-$51M	-$23M	-116.0%